NO20076021L - Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme - Google Patents

Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme

Info

Publication number
NO20076021L
NO20076021L NO20076021A NO20076021A NO20076021L NO 20076021 L NO20076021 L NO 20076021L NO 20076021 A NO20076021 A NO 20076021A NO 20076021 A NO20076021 A NO 20076021A NO 20076021 L NO20076021 L NO 20076021L
Authority
NO
Norway
Prior art keywords
amyloid
antibodies directed
same
methods employing
beta peptide
Prior art date
Application number
NO20076021A
Other languages
English (en)
Norwegian (no)
Inventor
Arnon Rosenthal
Jaume Pons
Wei-Hsien Ho
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076021(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of NO20076021L publication Critical patent/NO20076021L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20076021A 2005-04-29 2007-11-22 Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme NO20076021L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67609305P 2005-04-29 2005-04-29
US70481805P 2005-08-01 2005-08-01
PCT/US2006/016071 WO2006118959A2 (en) 2005-04-29 2006-04-28 Antibodies directed against amyloid-beta peptide and methods using same

Publications (1)

Publication Number Publication Date
NO20076021L true NO20076021L (no) 2008-01-28

Family

ID=37308500

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076021A NO20076021L (no) 2005-04-29 2007-11-22 Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme

Country Status (30)

Country Link
US (4) US7763250B2 (he)
EP (1) EP1877442B1 (he)
JP (1) JP4280300B2 (he)
KR (2) KR101130874B1 (he)
CN (1) CN102617733B (he)
AP (1) AP2007004217A0 (he)
AR (1) AR053252A1 (he)
AU (1) AU2006242546B2 (he)
BR (1) BRPI0607671A2 (he)
CA (1) CA2605759C (he)
CR (1) CR9478A (he)
DK (1) DK1877442T3 (he)
DO (1) DOP2006000099A (he)
EA (1) EA016193B9 (he)
ES (1) ES2597403T3 (he)
GE (1) GEP20125385B (he)
GT (1) GT200600182A (he)
HK (1) HK1117543A1 (he)
IL (1) IL186671A (he)
MA (1) MA29409B1 (he)
MX (1) MX2007013626A (he)
MY (1) MY148086A (he)
NO (1) NO20076021L (he)
NZ (1) NZ562589A (he)
PE (1) PE20061323A1 (he)
SV (1) SV2008002511A (he)
TN (1) TNSN07401A1 (he)
TW (1) TWI501975B (he)
UY (1) UY29504A1 (he)
WO (1) WO2006118959A2 (he)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
JP5486808B2 (ja) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
DK2361638T3 (en) 2005-12-12 2014-03-03 Ac Immune Sa Beta-1-42-specific monoclonal antibodies with therapeutic properties
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
SI2099826T1 (sl) * 2007-01-05 2014-02-28 University Of Zurich Prorektorat Forschung Anti-beta-amiloidno protitelo in njegova uporaba
IL199534A (he) 2007-01-05 2013-01-31 Univ Zuerich נוגדן הומאני מבודד המסוגל לזהות neoepitope בחלבון הקשור למחלה, פולינוקלאוטיד שמקודד לנוגדן, וקטור המכיל את פולינוקליאוטיד, תא מארח המכיל את הפולינוקליאוטיד או הווקטור, תכשיר המכיל את הנוגדן ושיטות ושימושים שקשורים לכל אלו
PL2104682T3 (pl) 2007-01-11 2017-03-31 Michael Bacher Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
WO2008154415A1 (en) * 2007-06-08 2008-12-18 New York University Stage specific prognostic in vivo markers of brain aging and dementia
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RU2475500C2 (ru) 2007-09-13 2013-02-20 Деленекс Терапьютикс Аг ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К β-АМИЛОИДНОМУ ПЕПТИДУ
AR068563A1 (es) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo mutante
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
RS53174B (en) 2007-10-05 2014-06-30 Genentech Inc. USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
CN105169388A (zh) * 2007-10-05 2015-12-23 基因技术公司 人源化抗体
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST PRITURE
DK2236604T3 (en) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
BRPI0819916A2 (pt) * 2007-12-11 2015-05-19 Glaxo Group Ltd Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
MY195714A (en) 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
DK2949666T3 (en) 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MA34025B1 (fr) 2010-03-03 2013-02-01 Boehringer Ingelheim Int Polypeptides se liant au bêta-a
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US9023607B2 (en) * 2010-04-26 2015-05-05 Intellectual Discovery Co., Ltd. Method for early diagnosis of alzheimer'S disease using phototransistor
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US8911731B2 (en) * 2011-07-15 2014-12-16 Janssen Pharmaceutica Nv Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
KR101503031B1 (ko) 2013-04-25 2015-03-18 한국화학연구원 아미노싸이올레이트를 이용한 납 전구체, 이의 제조방법, 및 이를 이용하여 박막을 형성하는 방법
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
PE20150153A1 (es) 2012-06-29 2015-02-05 Pfizer 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
FR3007988B1 (fr) * 2013-07-04 2015-09-25 Centre Nat Rech Scient Inhibition de la synthese de la proteine betaapp ou de l'activite du peptide abeta dans les plexus choroides.
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
WO2015053624A2 (en) * 2013-10-07 2015-04-16 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antisense oligonucleotide directed removal of proteolytic cleavage sites, the hchwa-d mutation, and trinucleotide repeat expansions
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
MD20160102A2 (ro) 2014-04-01 2017-04-30 Pfizer Inc. Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
SG11201607896YA (en) 2014-04-10 2016-10-28 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
AU2015262399B9 (en) * 2014-05-22 2021-07-22 National Center For Geriatrics And Gerontology Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
EP3177624B1 (en) 2014-08-06 2019-05-01 Pfizer Inc Imidazopyridazine compounds
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
DK3253755T3 (da) 2015-02-03 2020-09-28 Pfizer Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20180004817A (ko) 2015-06-17 2018-01-12 화이자 인코포레이티드 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
SG11201806383TA (en) 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
ES2878160T3 (es) 2016-07-01 2021-11-18 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para el tratamiento de enfermedades neurológicas y neurodegenerativas
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11312713B2 (en) 2017-03-10 2022-04-26 Pfizer Inc. Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
AU2018230109B2 (en) 2017-03-10 2022-05-12 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
BR112019026955A2 (pt) 2017-06-22 2020-06-30 Pfizer Inc. derivados de di-hidro-pirrolo-piridina
EP3431496A1 (en) * 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
IL272773B1 (he) 2017-08-22 2024-02-01 Biogen Ma Inc תכשירי רוקחות המכילים נוגדנים אנטי-בתא אמילואיד
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
TWI801540B (zh) 2018-03-23 2023-05-11 美商輝瑞大藥廠 哌嗪氮雜螺衍生物
CN114401992A (zh) 2019-07-05 2022-04-26 艾欧麦克斯治疗股份公司 结合igsf11（vsig3）的igc2的抗体及其用途
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
WO2022008027A1 (en) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
AU2021374803A1 (en) 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4403112A (en) 1981-05-18 1983-09-06 Modafferi Acoustical Systems, Ltd. Phase shift low frequency loudspeaker system
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4891268A (en) 1984-03-26 1990-01-02 Metal Coatings International Inc. Coated metal substrates with anticorrosion coating composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5525339A (en) 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
JPH05506990A (ja) 1990-04-24 1993-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114324D0 (en) 1991-07-03 1991-08-21 Kontor Moulding Systems Ltd Injection moulding of thermoplastic polymers
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5962463A (en) 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
WO1994009370A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JPH09506170A (ja) 1993-10-20 1997-06-17 デューク・ユニヴァーシティ β‐アミロイドペプチドに物質を結合する方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US5525126A (en) 1994-10-31 1996-06-11 Agricultural Utilization Research Institute Process for production of esters for use as a diesel fuel substitute using a non-alkaline catalyst
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
AU7142796A (en) 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
WO1998009523A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5976817A (en) 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6221670B1 (en) 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1002862A1 (en) 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Methods of diagnosing or treating neurological diseases
US6143171A (en) 1999-04-07 2000-11-07 Van Aarsen; Freda Martha Magnetic device for treatment of fluids
AU4753900A (en) 1999-05-03 2000-11-17 Evotec Biosystems Ag Methods of diagnosing or treating alzheimer's disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
JP5249482B2 (ja) 1999-06-16 2013-07-31 ボストン・バイオメデイカル・リサーチ・インステイテユート インビボのβ−アミロイドレベルの免疫学的制御
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1353944A2 (en) 2000-04-05 2003-10-22 The University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
WO2002025279A2 (en) 2000-09-19 2002-03-28 Evotec Neurosciences Gmbh Use of amyloid precursor protein for treating brain amyloidosis
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002080244A2 (en) 2001-02-12 2002-10-10 Asm America, Inc. Improved process for deposition of semiconductor films
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US6573276B2 (en) 2001-05-09 2003-06-03 Boehringer Ingelheim Pharma Kg Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesis
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1429805A4 (en) 2001-08-17 2005-09-21 Lilly Co Eli USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B)
CA2504349A1 (en) 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid
EP1469877A4 (en) 2001-11-02 2008-08-20 Tanox Inc B-cell lymphoma-specific antigen for use in the diagnosis and treatment of malignant B cell lesions
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003086310A2 (en) * 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
ES2318123T3 (es) 2002-04-25 2009-05-01 Eli Lilly And Company Procedimiento para tratar la ansiedad en sujetos de edad avanzada.
AUPS306402A0 (en) 2002-06-20 2002-07-11 Aguilar, Marie-Isabel Assay method
CA2489350A1 (en) 2002-06-20 2003-12-31 Axonyx, Inc. Method for identifying drugs for the treatment of alzheimer's disease
ES2201929B1 (es) 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
CA2498407A1 (en) 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
PL215171B1 (pl) 2002-12-24 2013-10-31 Rinat Neuroscience Corp Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
KR20060054174A (ko) 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
ES2246105B1 (es) 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005011599A2 (en) 2003-08-01 2005-02-10 Northwestern University Antibodies specific for toxic amyloid beta protein oligomers
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.

Also Published As

Publication number Publication date
GT200600182A (es) 2007-02-14
AR053252A1 (es) 2007-04-25
CN102617733B (zh) 2016-01-20
KR20080005231A (ko) 2008-01-10
WO2006118959A2 (en) 2006-11-09
US20130236451A1 (en) 2013-09-12
EP1877442A2 (en) 2008-01-16
KR100994599B1 (ko) 2010-11-15
HK1117543A1 (en) 2009-01-16
SV2008002511A (es) 2008-04-11
AP2007004217A0 (en) 2007-10-31
TWI501975B (zh) 2015-10-01
CA2605759A1 (en) 2006-11-09
IL186671A (he) 2014-01-30
DK1877442T3 (en) 2016-09-26
AU2006242546B2 (en) 2011-04-21
KR101130874B1 (ko) 2012-03-28
GEP20125385B (en) 2012-01-25
UY29504A1 (es) 2006-10-31
NZ562589A (en) 2009-07-31
AU2006242546A1 (en) 2006-11-09
US20060292152A1 (en) 2006-12-28
KR20100120242A (ko) 2010-11-12
US7763250B2 (en) 2010-07-27
EA200702095A1 (ru) 2008-04-28
TNSN07401A1 (fr) 2009-03-17
CR9478A (es) 2007-12-04
EP1877442B1 (en) 2016-08-17
JP2008538925A (ja) 2008-11-13
MX2007013626A (es) 2008-01-24
US20110044985A1 (en) 2011-02-24
EA016193B9 (ru) 2012-08-30
TW200718710A (en) 2007-05-16
ES2597403T3 (es) 2017-01-18
WO2006118959A3 (en) 2007-05-10
CA2605759C (en) 2014-06-10
MY148086A (en) 2013-02-28
BRPI0607671A2 (pt) 2009-09-22
IL186671A0 (en) 2008-01-20
DOP2006000099A (es) 2006-10-31
MA29409B1 (fr) 2008-04-01
US20160096884A1 (en) 2016-04-07
JP4280300B2 (ja) 2009-06-17
PE20061323A1 (es) 2007-02-09
CN102617733A (zh) 2012-08-01
EA016193B1 (ru) 2012-03-30
US8398978B2 (en) 2013-03-19

Similar Documents

Publication Publication Date Title
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
NO20083793L (no) Antistoffer mot amyloid-beta peptid
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
NO20090156L (no) Humanisert antistoff
ECSP13012609A (es) Composición farmacéutica
CR8108A (es) Tratamiento con anticuerpos anti-vegf
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
MX2011010353A (es) Composicion farmaceutica.
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
DE602006008460D1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
EA200701031A1 (ru) Молекулы, способствующие гематопоэзу
EA202190387A1 (ru) Антитело к cd38 человека и его применение
CU23668A3 (es) Anticuerpos dirigidos contra el péptido beta-amiloide y métodos de usar los mismos
CR8883A (es) Anticuerpos dirigidos contra peptido beta-amiloide y procedimientos que usan los mismos
WO2010053877A3 (en) Mhc ii associated protein and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application